HLA-A and neoplasm: All three TCRs responded to PIK3CAH1047L-bearing HLA-A*11:01 positive tumor cell lines, whereas the lack of HLA-A*11:01 failed to demonstrate anti-tumor reactivity (Fig. 4c, d).